Cagrilintide
Long-acting amylin analog investigated for obesity/weight management (incl. combinations such as CagriSema). Not a supplement.
Stacks containing Cagrilintide
Public community stacks that include this ingredient.
Peptides 💀💀💀
Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).
Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly) produced an estimated mean body-weight reduction of -20.4% vs -3.0% with placebo at week 68 (P<0.001), superior to either component alone. GI adverse events were common (majority transient and mild-to-moderate). Published in NEJM 2025.
CagriSema produced mean weight loss of -13.7% vs -3.4% with placebo at week 68, and 73.5% of patients achieved HbA1c ≤6.5% vs 15.9% with placebo. GI adverse events in 72.5% of CagriSema group (mostly transient/mild-moderate). Published in NEJM 2025.
Reuters news report (February 2026) described CagriSema outperforming semaglutide in a late-stage diabetes trial; this is now confirmed by the peer-reviewed REDEFINE 2 NEJM paper (see above).